Cardiol Therapeutics Files Definitive Agreements for $14.85M Bought Deal Financing

summarizeSummary

Cardiol Therapeutics has filed the definitive underwriting agreement and warrant indenture for its previously announced $14.85 million bought deal financing, which closed on January 23, 2026.

check_boxKey Events

• Formalizes Bought Deal Financing

  Cardiol Therapeutics filed the definitive Underwriting Agreement and Warrant Indenture for its $14.85 million bought deal financing, which closed on January 23, 2026.

• Offering Structure and Pricing

  The financing involved 11,423,078 units sold at $1.30 per unit, with each unit consisting of one common share and one-half common share purchase warrant.

• Warrant Terms

  The 5,711,539 warrants are exercisable at $1.75 per common share until January 23, 2028.

• Significant Capital Infusion

  This transaction provides a substantial capital raise for the company, following its announcement of surpassing 50% patient enrollment in its pivotal Phase III MAVERIC trial on January 13, 2026.

auto_awesomeAnalysis

This 6-K filing formalizes the terms of the $14.85 million bought deal financing that Cardiol Therapeutics previously announced on January 16, 2026, and closed on January 23, 2026. The filing includes the definitive Underwriting Agreement and Warrant Indenture, providing full legal details of the transaction. The financing involved the sale of units at $1.30, a premium to the current stock price, with each unit comprising one common share and one-half warrant exercisable at $1.75. While the market has largely absorbed the news of this capital raise, the detailed documentation confirms the terms of this significant funding event. The capital infusion is substantial relative to the company's market capitalization and is expected to support its ongoing operations, including its pivotal Phase III MAVERIC trial. Investors should note the dilutive impact from the issuance of new shares and the potential for further dilution upon warrant exercise.